Sandoz Reports Strong Financial Results and Forecasted Growth for 2026

Sandoz Group AG, a leader in affordable medicines, disclosed its financial outcomes for 2025, showcasing robust performance with net sales reaching USD 11.1 billion, reflecting a 7% increase. The biosimilars sector notably surged by 15%, marking the company's continued expansion in this domain. Core EBITDA rose 16%, fortifying the company's profitability.

CEO Richard Saynor highlighted 2025 as a transformative year, characterized by progression in Sandoz's biosimilars pipeline and significant launches, such as Pyzchiva and Tyru,o in the US, and Afqlir in Europe. Sandoz expects further growth in 2026, driven by recent launches and operational efficiencies.

Despite positive projections, the company faced challenges in its generics sector due to trade dynamics affecting API sales. Sandoz anticipates a return to equilibrium but remains vigilant of market influences.